Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer | springermedizin.de
Bezzera Siebträger 2 er Auslauf passend für alle Bezzera E 61 Brühgruppen